Search the Newsreel

Pulse Biosciences (NASDAQ:PLSE) Sets New 1-Year High - Time to Buy?

Pulse Biosciences (NASDAQ:PLSE) stock reached a new 52-week high of $46.03, closing at $46.75, despite reporting weaker-than-expected quarterly results. Analyst sentiment is mixed, with a "Moderate Buy" consensus but an average price target below the current trading price. Institutional investors hold a significant 76.95% …

Why Did CuriosityStream Stock Rocket Higher Today?

CuriosityStream (NASDAQ: CURI) stock rocketed over 50% after releasing its second-quarter earnings last night. There were good reasons for the massive move, too. Shares of the company aren't soaring because of its on-demand streaming service. Rather, it is due to the company's move to …

Citizens cuts Spruce Biosciences stock price target on share dilution

Citizens has lowered its price target for Spruce Biosciences (NASDAQ: SPRB) from $150.00 to $144.00, citing potential share dilution indicated in the company's 10-Q filing, while maintaining a Market Outperform rating. Despite the reduction, the new target still suggests significant upside, though InvestingPro data …

Artelo Biosciences Releases Q2 2026 Financial Results

Artelo Biosciences, Inc. reported a net loss of $2.4M and a loss of $0.89 per share for Q2 2026, marking a significant improvement from the $16.8 per-share loss in Q2 2025. The clinical-stage biopharmaceutical company continues to advance its therapeutic pipeline targeting lipid-signaling pathways, …

Agios Pharmaceuticals faces investigation after halting sickle cell drug development, stock drops 6.74%.

Agios Pharmaceuticals is under investigation by Pomerantz LLP for potential securities fraud after its stock fell 6.74%. This drop occurred following the company's announcement to cease development of tebapivat, a sickle cell disease drug, due to disappointing Phase 2 trial results. Investors affected by …

Assenagon Asset Management S.A. Has $3.86 Million Stock Holdings in Agios Pharmaceuticals, Inc. $AGIO

Assenagon Asset Management S.A. significantly increased its stake in Agios Pharmaceuticals, Inc. by 54.8% during the second quarter, bringing its total holdings to 103,955 shares valued at $3.86 million. This increase occurred despite Agios Pharmaceuticals reporting a slightly wider-than-expected quarterly loss of $1.69 per …

Artelo Plans Q4 Trial After ART26.12 Matches Naproxen for Pain

Artelo Biosciences reported its Q2 2026 financial results, with a narrowed net loss of $2.4 million and positive pipeline updates. The company plans a Phase 1 multiple ascending dose study for ART26.12 in Q4 2026, which has shown pain relief comparable to naproxen in …

Morgan Stanley Has Lowered Expectations for Neurocrine Biosciences (NASDAQ:NBIX) Stock Price

Spruce Biosciences (NASDAQ:SPRB) Given New $144.00 Price Target at Citizens Jmp

Citizens Jmp has reduced its price target for Spruce Biosciences (NASDAQ:SPRB) to $144.00 from $150.00 but maintained a "market outperform" rating, indicating a potential upside of nearly 199%. Despite a wider-than-expected quarterly loss of $6.68 per share, analyst sentiment remains largely positive with a …

Artelo Biosciences (ARTL) investors disclose 4.8% stake via Intracoastal warrant

Mitchell P. Kopin, Daniel B. Asher, and Intracoastal Capital LLC have disclosed a 4.8% beneficial ownership stake in Artelo Biosciences (ARTL) through a warrant held by Intracoastal. This ownership amounts to 173,914 shares of common stock, issuable upon the warrant's exercise, and is based …

Kuros Biosciences erzielt im ersten Halbjahr 2026 Gewinn bei 45 % Umsatzwachstum

Pulse Biosciences stock reaches all-time high at 46.03 USD By Investing.com

Pulse Biosciences Inc. (PLSE) stock hit an all-time high of $46.03, currently trading near its 52-week high of $45.90, despite a recent report of wider-than-expected Q2 2026 losses and lower revenue. The stock has seen a significant 163.78% one-year increase and 216% year-to-date, boosting …

Twist Bioscience stock hits 52-week high at 126.22 USD

Twist Bioscience stock reached a new 52-week high of $126.22, trading just 1% below this peak and marking a remarkable 440% surge from its 52-week low. The company also reported strong fiscal third-quarter 2026 revenues of $118.4 million, exceeding Wall Street estimates, although adjusted …

Cogent Biosciences (COGT) May Find a Bottom Soon, Here's Why You Should Buy the Stock Now

Lexaria Enters a Material Transfer Agreement With PegBio

Lexaria Bioscience Corp. has signed a Material Transfer Agreement (MTA) with PegBio Co., Ltd to evaluate Lexaria's DehydraTECH technology with PegBio's proprietary GLP-1 molecule for the GLP-1 industry. This collaboration aims to enhance the accessibility and effectiveness of PegBio's GLP-1-related drug products, which target …

Earnings call transcript: Cellectar narrows focus on WM as Q2 2026 loss widens

Cellectar Biosciences reported a wider-than-expected Q2 2026 loss of $0.57 per share, but its stock rose in premarket trading due to a stronger cash position and clinical progress for its lead drug, iopofosine I-131, in Waldenstrom’s macroglobulinemia (WM). The company secured up to $140 …

Avoiding Lag: Real-Time Signals in (TYRA) Movement

The article analyzes Tyra Biosciences Inc. (NASDAQ: TYRA), highlighting weak near-term and mid-term sentiment despite a long-term positive outlook. It provides AI-generated institutional trading strategies including position, momentum breakout, and risk hedging, along with multi-timeframe signal analysis and support/resistance levels.

CURI Stock Jumps As Record Q2 2026 Earnings Lift Guidance

Alamar Biosciences, Inc. (ALMR) Q2 2026 Earnings Report - Results, Call & Slides

Alamar Biosciences, Inc. (ALMR) reported its Q2 2026 earnings, beating both EPS and revenue expectations. The company posted an actual EPS of -$0.22 against a consensus of -$0.31, and actual revenue of $29.40 million compared to an expected $25.86 million. The earnings call took …

News by ACCESS Newswire on TradingView, 2026-08-13

Lexaria Bioscience Corp. has announced a Material Transfer Agreement (MTA) with PegBio Co., Ltd to explore Lexaria's DehydraTECH technology with a proprietary PegBio GLP-1 molecule for the GLP-1 industry. This collaboration aims to evaluate the pharmacokinetic performance of the combined technology in animal studies, …

CURI Stock Jumps As Record Q2 Earnings Fuel AI Momentum

Microbix Biosystems Q3 2026 Earnings Call Transcript

Earnings Flash (MBX.TO) Microbix Biosystems Inc. Reports Q3 Revenue C$4.1M

HC Wainwright Has Bullish Outlook for DTIL FY2030 Earnings

Artelo Biosciences Provides Business Update and Reports 2026 Second Quarter Financial Results

Artelo Biosciences Clinical and Scientific Progress Across the Pipeline Supports Multiple Upcoming Milestones SOLANA BEACH, Calif., Aug. 13, 2026 (GLOBE NEWSWIRE) -- Artelo Biosciences, Inc. (Nasdaq: ARTL) ("Artelo" or the "Company"), a clinical-stage pharmaceutical company focused on modulating lipid-signaling pathways to develop treatments for …

Cellectar Reports Q2 2026 Results, Strengthened Cash Positions Supports Oncology Pipeline

(RTTNews) - Cellectar Biosciences, Inc. (CLRB) reported second-quarter 2026 results, highlighting increased R&D investment and a stronger balance sheet compared to the prior year. The company advanced its oncology pipeline with progress in pivotal and early-stage trials, while preparing for a Phase 3 confirmatory …

Kuros Biosciences AG legt Ergebniszahlen für das Halbjahr bis zum 30. Juni 2026 vor

CURI Stock Pops As Record Q2 Earnings Fuel AI Licensing Story

CURI Stock Jumps As Record Earnings, AI Deals Lift Outlook

Cellectar Biosciences (CLRB) Q2 loss hits $6.9M as cash reaches $34M

Cellectar Biosciences reported a net loss of $6.9 million for Q2 2026, an increase from $5.4 million in Q2 2025, driven by higher R&D expenses. The company's cash and cash equivalents rose to $34.0 million, up from $13.2 million at the end of 2025, …

Cellectar Prepares ~100-Patient-Per-Arm Trial, Plans 2027 FDA Filing

Cellectar Biosciences reported its Q2 2026 financial results, including a $6.9 million net loss, and provided significant corporate updates. The company is advancing its radiotherapeutic pipeline, most notably initiating site activation for a Phase 3 confirmatory trial for iopofosine I 131 in Waldenström macroglobulinemia, …

Cellectar Biosciences Reports Second Quarter 2026 Financial Results and Provides Corporate Updates

Cellectar Biosciences announced its second-quarter 2026 financial results and provided a corporate update, highlighting progress in its oncology pipeline. Key developments include the initiation of site activation for a confirmatory Phase 3 study of iopofosine I 131 in Waldenström Macroglobulinemia (WM), with an NDA …

Emergent Biosolutions (NYSE:EBS) Rating Increased to Hold at Zacks Research

Zacks Research upgraded Emergent BioSolutions (NYSE:EBS) to a "Hold" rating. Despite beating Q2 earnings estimates, the company faces analyst forecasts for a full-year loss, increased competition, and pricing pressure, leading to a significant impairment charge against its NARCAN franchise. The stock currently has a …

Deutsche Bank Adjusts Neurocrine Biosciences PT to $165 From $190, Maintains Hold Rating

Deutsche Bank has adjusted its price target for Neurocrine Biosciences (NBIX) to $165, down from $190, while maintaining a Hold rating on the stock. This adjustment comes amidst recent news including positive Phase 4 study results for Ingrezza capsules and the initiation of a …

Microbix Biosystems Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended June 30, 2026

HC Wainwright Analysts Increase Earnings Estimates for JBIO